Zentek Ltd. (NASDAQ:ZTEK - Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 156,100 shares, a growth of 79.8% from the August 31st total of 86,800 shares. Approximately 0.2% of the company's shares are short sold. Based on an average trading volume of 289,800 shares, the short-interest ratio is currently 0.5 days. Based on an average trading volume of 289,800 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the company's shares are short sold.
Zentek Stock Down 1.0%
Shares of Zentek stock opened at $0.78 on Friday. The stock's fifty day moving average is $0.83 and its 200-day moving average is $1.12. Zentek has a 12-month low of $0.50 and a 12-month high of $1.84. The company has a quick ratio of 1.30, a current ratio of 1.62 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $81.69 million, a PE ratio of -15.60 and a beta of 0.90.
Zentek (NASDAQ:ZTEK - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.01) EPS for the quarter. Zentek had a negative net margin of 981.17% and a negative return on equity of 55.41%. The firm had revenue of $0.04 million during the quarter.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Zentek in a report on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Zentek presently has an average rating of "Sell".
View Our Latest Report on ZTEK
About Zentek
(
Get Free Report)
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zentek, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentek wasn't on the list.
While Zentek currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.